VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

VJVirtual | PD-1/VEGFR blockade for liver cancer

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, discusses the use of combined PD-1/VEGFR blockade for the treatment of hepatocellular cancer, highlighting promising results with bevacizumab and atezolizumab in combination, and comparing this approach to strategies being employed in the treatment of lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter